KromaTiD receives $2M of growth investment from BroadOak Capital Partners

KromaTiD receives $2M of growth investment from BroadOak Capital Partners

LONGMONT -- KromaTiD announced BroadOak Capital Partners made a $2M investment in the company. KromaTiD said its sales and operations are rapidly accelerating, driven by growing market... Read More

Thursday April 29, 2021 0 comments Tags: Longmont, KromaTid, BroadOak Capital Partners, Christopher Tompkins

KromaTiD announces addition of James Chomas to board of directors

KromaTiD announces addition of James Chomas to board of directors

LONGMONT -- KromaTiD announced Colorado biomedical entrepreneur James Chomas has joined the company's board of directors. Chomas has a track record of developing innovative healthcare... Read More

Friday February 12, 2021 0 comments Tags: Longmont, KromaTid, James Chomas, Christopher Tompkins

KromaTiD announces appointment of Vic Myer to board of directors

KromaTiD announces appointment of Vic Myer to board of directors

LONGMONT -- KromaTiD, Inc. announced the appointment of Vic Myer to its board of directors. Myer joins KromaTiD's board with extensive experience in technology, RD and pharmaceutical company... Read More

Wednesday September 23, 2020 0 comments Tags: Longmont, Vic Myer, Christopher Tompkins, KromaTid

KromaTiD awarded Direct to Phase II SBIR grant by the National Human Genome Research Institute

KromaTiD awarded Direct to Phase II SBIR grant by the National Human Genome Research Institute

LONGMONT -- KromaTiD, Inc. today announced it has been awarded a Direct to Phase II SBIR grant by the National Human Genome Research Institute. The award supports development of a structural... Read More

Monday August 24, 2020 0 comments Tags: Longmont, KromaTid, National Human Genome Research Institute, Christopher Tompkins

KromaTiD announces launch of dGH In-Site

KromaTiD announces launch of dGH In-Site

LONGMONT -- KromaTiD, Inc. announced the launch of its new productdGH In-Site, a single-cell, high resolution, genome-wide DNA insert tracking assay. dGH In-Site enables researchers to directly... Read More

Wednesday June 10, 2020 0 comments Tags: Longmont, KromaTid, Christopher Tompkins, dGH In-Site

KromaTiD appoints Christopher Tompkins new company chief executive

KromaTiD appoints Christopher Tompkins new company chief executive

LONGMONT -- KromaTiD, Inc. announced the appointment of Christopher Tompkins as CEO. Tompkins, who joined the company in 2010, most recently served as president, GM and chief technology... Read More

Wednesday June 26, 2019 0 comments Tags: Longmont, KromaTid, Christopher Tompkins

KromaTiD receives $900K in funding from Human Genome Research Institute

KromaTiD receives $900K in funding from Human Genome Research Institute

FORT COLLINS-- KromaTiD, Inc . announced that after successfully meeting Phase 1 grant milestones, the company has been awarded Phase 2 funding from a Fast Track Small Business Innovation... Read More

Wednesday April 24, 2019 0 comments Tags: Fort Collins, KromaTid, Christopher Tompkins

KromaTiD announces opening of new corporate headquarters in Longmont

KromaTiD announces opening of new corporate headquarters in Longmont

LONGMONT -- KromaTiD, Inc. today announced the opening of the companys new corporate headquarters inColorado'sBoulder Countybiotech hub. The new facility includes corporate offices as well... Read More

Thursday March 28, 2019 0 comments Tags: Longmont, KromaTid, Christopher Tompkins